Tag: psoriasis

Clinical Research: Phase 1 - Phase 4

3 Strategies for Treating Psoriasis

We’ve previously discussed several issues around psoriasis, including the pathogenesis of the condition and the challenges (and solutions!) of conducting psoriasis clinical trials. Today we turn toward three strategies for treating it. Although moisturizer may be an effective solution for some cases of mild psoriasis, many patients require medical intervention to ease their symptoms and...

Clinical Research: Phase 1 - Phase 4

Biologics in Psoriasis Treatment

Biologics have revolutionized psoriasis treatment over the last two decades. These targeted immunomodulatory therapies act directly on the cytokine pathways that are upregulated in psoriasis and other autoimmune diseases. Two major classes make up biologics in psoriasis treatment: tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors. TNF Inhibitors TNF inhibitors became the first available biologic...

Consulting

The Complicated Pathogenesis of Psoriasis

Psoriasis is an autoimmune disease that affects 7.5 million people in the United States and roughly 100 million worldwide. While its main manifestation is in unsightly, often irritating skin lesions, many patients also experience painful psoriatic arthritis. Additionally, psoriasis often comes with a wide range of other chronic conditions, including Type 2 diabetes, cardiovascular disease and...

Consulting

Psoriasis: An Introduction

A systemic disease with a variety of comorbidities, psoriasis is a common condition with several clinical subtypes. In this white paper, we discuss the pathogenetic and clinical aspects of psoriasis, as well as the nuances of designing and conducting psoriasis clinical trials.

Consulting

The Changing Landscape of Psoriasis Treatment

Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis, with more than half of treated patients now able to achieve essentially complete clearing of their disease. In this white paper, we will explore the history of psoriasis treatment – including topical and oral therapies – and the evolution of biologics.

Clinical Research: Phase 1 - Phase 4

Challenges and Solutions in Conducting Psoriasis Clinical Trials

Designing and conducting psoriasis clinical trials is tricky. After all, psoriasis is a highly variable group of conditions that produce a range of debilitating and often subjective symptoms. So how do researchers assess efficacy in novel psoriasis treatments? Read on for the answer. Considerations for Psoriasis Trials In clinical practice, broad global assessments are used...

Consulting

More Than Skin Deep: Beyond the Dermatological Manifestations of Psoriasis

Psoriasis is caused by dysregulated interactions of the innate and adaptive immune system in skin epithelium and connective tissue, including the activation and proliferation of T helper cells. As an autoimmune disorder causing widespread inflammation, it is unsurprising that psoriasis is associated with a number of non-dermatological conditions. Continued psoriasis research may give insight into the etiology...

Consulting

Understanding Psoriasis

Psoriasis is a dermatological disorder that is often paired with underlying systemic disease and multiple comorbidities. While a common condition, its wide range of severity and causes, along with several clinical subtypes, make it challenging to treat. Global Impact of Psoriasis The World Health Organization estimates at least 100 million individuals globally live with psoriasis,...